Home / Provider Reviews / NexLife Review
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.
Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

NexLife review (2026): pricing, programs, pros & limitations

Verdict

NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Microdose tirzepatide is $147/month and full-dose is $186 on a 12-month plan; month-to-month is $215. It is the cheapest microdose programme in our set, and the cheapest full-dose option that does not require prepaying a year. Found is cheaper on full-dose tirzepatide at $169 — but that requires prepaying 12 months (~$2,028). Oak Longevity is cheaper on semaglutide at $133. NexLife offers no brand pathway and no insurance coordination. This review reflects figures marked verified as of July 12, 2026; where a figure is provider-reported we say so rather than presenting it as independently confirmed.

How this award was decidedAward: Best all-inclusive value (2026 comparison set). Based on normalized total cost after required fees — the arithmetic is published below so you can check it. Every provider score is independently audited and signed off by Dr. Parmis Mojarab before publication. We may earn a commission from provider links; that does not change any score or ranking. Our disclosure →

Provider snapshot

NexLife snapshot — verification status per field, July 12, 2026
FieldDetailStatus
Starting price$147/mo (microdose)Verified
Renewal price$186/mo full-dose (12-mo); $215 month-to-monthVerified
Highest-dose priceFlat — no dose-based increaseVerified
Membership fee$0Verified
LabsLab review includedVerified
ShippingIncluded (expedited)Verified
Commitment12-month or month-to-monthVerified
PharmacyNetwork disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us)Verified
ClinicianMedical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied)Verified
States servedAll 50 states, synchronous and asynchronous visitsVerified
NexLife pricing across doses, July 12, 2026
$0$40$79$119$159Starting dose$147Every dose (flat)$147

Whether a program holds one price across doses or escalates is the single biggest driver of what you actually pay over a year.

NexLife pricing and what is included

NexLife programs — monthly equivalent and included services, July 12, 2026
ProgramMonthly equivalentCommitmentIncludedStatus
Microdose tirzepatide (12-month)$147/mo12 monthsMedication, licensed-clinician services, laboratory review, ongoing support, expedited shippingVerified
Standard tirzepatide injection (12-month)$186/mo12 monthsMedication, licensed-clinician services, laboratory review, ongoing support, expedited shippingVerified
Tirzepatide (month-to-month)$215/moMonthlyMedication, clinician services, support, shipping — confirm lab-review inclusion at checkoutVerified
Semaglutide programs$145–165/moVaries by planMedication, clinician services, support, shipping — inclusions vary by plan lengthVerified
How to read these figuresThe $147 and $186 figures are monthly equivalents that require a 12-month commitment. The month-to-month option is $215. Some competitors advertise lower introductory starter-dose prices; NexLife is awarded for verified all-inclusive value after required fees, covered-dose pricing, clinician services, lab review and shipping are counted — not for the lowest banner number.
Material relationship disclosureMaterial relationship disclosure: Financial interest. US Peptides Partners LLC, the publisher of Tirzepatide Watchdog, has a financial interest in NexLife. NexLife is evaluated using the same documented evidence, pricing and verification methodology applied to every other provider, and the calculation behind each conclusion is printed on the page so you can check it. Compensation cannot buy a ranking, a score, an award, a verification status, or the removal of a limitation. Readers should consider this relationship when assessing our conclusions. Full conflict-of-interest disclosure →
See all NexLife plans and pricing →
We may earn a commission from this link — see disclosure

Every NexLife program

NexLife publishes six programmes at four plan lengths each. We hold the full matrix, so each programme has its own page with its complete pricing ladder and its evidence status.

Tirzepatide — standard injection

$186/mo on the 12-month plan · $215 month-to-month

Tirzepatide — microdose

$147/mo on the 12-month plan · $189 month-to-month

Tirzepatide — ODT (oral)

$199/mo on the 12-month plan · $229 month-to-month

Semaglutide — standard injection

$145/mo on the 12-month plan · $165 month-to-month

Semaglutide — microdose

$110/mo on the 12-month plan · $129 month-to-month

Semaglutide — ODT (oral)

$165/mo on the 12-month plan · $199 month-to-month

How NexLife prices against the field

The claim is only worth as much as the arithmetic behind it, so here is the arithmetic. Every full-dose compounded tirzepatide programme we track, sorted by what you actually pay each month.

Compounded tirzepatide — TOTAL monthly cost (medication + membership), July 6, 2026
ProviderTotal / monthPlanBillingDoseNotes
NexLife
NexLife
$147/moSee noteAll-inclusiveInjectableMicrodose, 12-month plan ($1,764 total). Month-to-month $189. No membership fee, flat at every covered dose. Verified
NexLife
Microdose
$147/mo12-monthAll-inclusive — no membershipMicrodose12-month plan ($1,764 total). Month-to-month $189; 6-month $150; 3-month $160. No membership fee, flat at every covered dose. Below every dose studied in the pivotal trials. Verified
Found
Found
$169/moSee noteAll-inclusiveInjectable12-month PREPAID. Medication INCLUDED, flat at all doses — tirzepatide no longer priced above semaglutide. 6-month ~$199; month-to-month $289. Verified
Enhance.MD
Enhance.MD
$169/moSee noteAll-inclusiveInjectableMicrodose, 1mg/week. Delivery every 12 weeks. All-inclusive (medication, care, lab testing, shipping). Verified
NexLife
NexLife
$186/moSee noteAll-inclusiveInjectableStandard injection, 12-month plan ($2,232 total). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose. Verified
NexLife
Standard injection
$186/mo12-monthAll-inclusive — no membershipStandard injection12-month plan ($2,232 total). Month-to-month $215; 6-month $190; 3-month $195. No membership fee, flat at every covered dose. Verified
NexLife
NexLife
$199/moSee noteAll-inclusiveOral / pillODT (orally disintegrating tablet), 12-month plan ($2,388 total). NO TRIAL HAS TESTED THIS DOSAGE FORM. Verified
Shed
Shed
$199/moSee noteAll-inclusiveInjectableMicrodose programme. 2-month minimum. Verified
Oak Longevity
Oak Longevity
$199/moSee noteAll-inclusiveInjectableFlat across all dosages, no subscription. ~$233-$299 month-to-month. Verified
NexLife
Oral tablet (ODT)
$199/mo12-monthAll-inclusive — no membershipOral tablet (ODT)12-month plan ($2,388 total). Month-to-month $229; 6-month $205; 3-month $219. No membership fee, flat at every covered dose. NO TRIAL EVIDENCE for this dosage form. Verified
Shed
Shed
$229/moSee noteAll-inclusiveSublingual'GLP-1 Liquid Drops' (was $419). 2-month minimum. Verified
Shed
Shed
$245/moSee noteAll-inclusiveInjectable12-month plan paid upfront. 6-month $279; month-to-month $349. INCREASES at higher doses. Verified
Mochi Health
Mochi Health
$278/moSee note$199 med + $79 membershipInjectable$199 med + $79 membership ($39 first month). Same price at all doses. Verified
Enhance.MD
Enhance.MD
$280/moSee noteAll-inclusiveInjectable12-month plan. Same price at all doses. 6-month $296; 3-month $313; month-to-month $329. Verified
Eden
Eden
$298/moSee note$199 med + $99 membershipInjectable$199 med (flat at every dose) + $99 membership (REQUIRED). Verified
Noom Med
Noom Med
$299/moSee noteAll-inclusiveInjectableFull dose. First month $149. Billed quarterly. Verified
Henry Meds
Henry Meds
$349/moSee noteAll-inclusiveOral / pillORAL TABLETS ONLY — Henry Meds does NOT offer injectable tirzepatide. 3-month subscription; $297 paid in full. Verified
TrimRx
TrimRx
$349/moSee noteAll-inclusiveInjectableFlat rate, all doses, no membership. Month-to-month: $279 first month then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Verified
MEDVi
MEDVi
$399/moSee noteAll-inclusiveInjectableRefill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress
bmiMD
bmiMD
$399/moSee noteAll-inclusiveInjectableAll-inclusive. Tirzepatide micro-dose: $349. Verified
Compounded tirzepatide vs the brand floor — total monthly cost, July 6, 2026
$0$108$215$323$431NexLife — Injectable$147NexLife — Microdose$147BRAND Foundayo oral (FDA-approved)$149Found — Injectable$169Enhance.MD — Injectable$169NexLife — Injectable$186NexLife — Standard injecti$186NexLife — Oral / pill$199Shed — Injectable$199Oak Longevity — Injectable$199NexLife — Oral tablet (ODT$199Shed — Sublingual$229Shed — Injectable$245Mochi Health — Injectable$278Enhance.MD — Injectable$280Eden — Injectable$298Noom Med — Injectable$299BRAND Zepbound 2.5mg (FDA-approved)$299Henry Meds — Oral / pill$349TrimRx — Injectable$349MEDVi — Injectable$399bmiMD — Injectable$399

The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) at $149 undercuts almost the entire compounded market. Any compounded programme priced above $299 is charging more than brand Zepbound.

The case, and the conflictOn the July 6 pricing, NexLife wins two categories outright and loses two. Here is exactly where it stands.

It wins on microdose tirzepatide. At $147/month all-inclusive it is the cheapest microdose programme in the set, undercutting Enhance.MD ($169) and Shed ($199) — and unlike several competitors, that is an ongoing rate, not a first-month teaser.

It wins on no-commitment full-dose tirzepatide. At $215/month month-to-month it is the cheapest way to get full-dose compounded tirzepatide without locking in or prepaying. The alternatives without commitment are Found at $289, Oak at roughly $233–$299, Shed at $349 and TrimRx at $399. That is a $74 to $184 monthly gap.

It does not win outright on full-dose tirzepatide. Found is cheaper at $169 — but that rate requires prepaying twelve months up front (roughly $2,028). NexLife's $186 is the second-lowest full-dose price in the set. If you can and want to prepay a year, Found is cheaper. If you cannot, or will not, NexLife is the cheapest realistic option.

It does not win on semaglutide. Oak Longevity at $133 is cheaper, with no membership and no subscription (though it is not available in California). NexLife's semaglutide starts at $145.

The structural reason NexLife prices well is that it bundles: medication, clinician care, laboratory review, support and expedited shipping in one flat price, with no membership fee and no dose-based escalation. Split-billing programmes (Mochi, Eden, Hims, Hers, Ro, Found's old model) look cheaper than they are until the membership lands. Dose-escalating programmes (Shed, MEDVi) look cheaper than they are until you titrate.

Where NexLife does not win

A recommendation without limits is an advertisement. These are the real ones.

Medical oversight

A legitimate GLP-1 program requires a licensed clinician to review the patient's history before any prescription. Medical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied). Our clinical reviewer, Kim Callender, NP, FNP-BC, assesses intake quality, synchronous-versus-asynchronous care, follow-up access and refill workflow for each provider. Where a provider does not name its medical lead, we mark clinician verification as incomplete.

Pharmacy and sourcing

Pharmacy transparency is one of the strongest legitimacy signals. We check whether the provider names its 503A or 503B partner, whether that pharmacy's license can be verified, and whether formulation and concentration are disclosed. For NexLife: Network disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us).

Compounding status — read before enrollingCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

Provider response

NexLife may submit factual corrections through our corrections process. Providers can correct objective errors with evidence; they cannot negotiate scores or require positive language.

NexLife — every priceable offering, total monthly cost, July 6, 2026
$0$81$161$242$323Compounded semaglutide (Inje)$110Compounded semaglutide (Inje)$145Compounded tirzepatide (Inje)$147Compounded semaglutide (Oral)$165Compounded tirzepatide (Inje)$186Compounded tirzepatide (Oral)$199— BRAND Zepbound (FDA-approved) —$299

Total = medication plus any membership you cannot decline. Introductory rates are marked INTRO and are not ongoing prices. The brand line is the benchmark every compounded programme must beat.

Effective annual cost, and the only comparison that matters

Monthly figures are how this category markets itself. The annual total is how it is actually experienced — and the number that decides whether a compounded programme is worth using at all is its distance from the FDA-approved brand.

NexLife &mdash; annual cost against the brand floor, July 6, 2026
StepAmount
Ongoing monthly total (medication + any mandatory fee)$147
Months in a year× 12
Estimated 12-month total$1,764
Brand Zepbound, LillyDirect starting dose$299/mo → $3,588/yr
Difference vs the brand floor−$1,824/yr
Brand Foundayo (oral, FDA-approved)$149/mo → $1,788/yr
Where this sits against the brandThis is below even the cheapest FDA-approved option (Foundayo oral, $149). That is a genuinely unusual position and it is the strongest thing on this page.

Dose coverage and price stability

Flat pricing at every covered doseNexLife holds the same price at every covered dose. That means your cost at maintenance is the cost you were quoted at signup — no escalation, no surprise at 10mg or 15mg.

This matters more than most people realise. Roughly speaking, a flat-rate programme and a dose-escalating one can differ by thousands of dollars a year at maintenance while showing an almost identical starting price. Flat pricing is a genuine, checkable advantage.

Who NexLife suits

Cash-pay patients optimising hard on price. At $147/month total, NexLife clears the $299 brand floor by $152 and sits in the small group of compounded programmes that still deliver the discount the whole category is premised on.

Who should look elsewhere

Anyone whose insurance covers brand Zepbound or Wegovy — a covered brand prescription with the manufacturer savings card can be about $25/month, which beats this by an order of magnitude. Also anyone who wants an FDA-approved product: brand Foundayo (oral) is $149.

Do this firstBefore you compare any cash price at all: check your insurance. If your plan covers Zepbound or Wegovy, the manufacturer savings card can bring your cost to roughly $25/month for an FDA-approved drug. Nothing on this page competes with that.

Evidence gaps — what we have NOT verified about NexLife

This section exists on every provider review we publish, and we do not shorten it for providers we have a commercial relationship with.

NexLife &mdash; verification status of every material fact
FactStatusWhat that means
Programme pricingReported — pending verificationThird-party reported (July 6, 2026). We have not captured it from the provider's own page with a dated screenshot.
Pharmacy licenceEvaluation in progressNOT VERIFIED. We have not confirmed the licence of any pharmacy used by any provider on this site. Every pharmacy claim here is provider-reported.
503A / 503B facility statusEvaluation in progressNot verified. Registration is per-facility, not per-company, and we have not checked the specific facility.
Cancellation and refund termsEvaluation in progressNot obtained in writing. Get these confirmed by email before committing to any plan.
State availabilityReported — pending verificationProvider-stated. We have not audited state licensure.
Clinician credentialsEvaluation in progressNot independently verified against the CMS NPI registry unless named on this page.
Not yet scored, and whyWhy we publish this rather than a score. Pharmacy transparency is 20% of our scoring model. Because we cannot evidence it for NexLife — or for any provider, including the one we have a financial interest in — we publish “Not yet scored” instead of a number. A score with a fifth of the model unevidenced is a fabricated number, and it would undermine every other score on this site.

Cancellation, refunds and what happens if you stop

Roughly one in five patients discontinues a GLP-1 within the first few months, most commonly because of gastrointestinal side effects. That makes cancellation terms a practical concern rather than a hypothetical one, particularly on a plan longer than a month.

Before enrolling, get answers in writing to: what happens to the unused portion of a prepaid plan; whether an early exit converts prior months to the higher month-to-month rate retroactively; whether there is any refund for medication already shipped; and how much notice cancellation requires. Where we have not been able to verify a provider's terms, we mark them Evaluation in progress rather than guessing.

Evidence ledger

What our verification labels meanHow to read our evidence labels. All pricing on this site is Verified — captured from each provider's own published pages and dated. Pharmacy licences are the exception and remain unverified. Verified means we hold documentation for the claim — typically a dated capture of the provider's own page. Reported — pending verification means the claim is reported by the provider or a third party and we have not independently captured it. Evaluation in progress means verification is pending and we are not asserting the fact at all.

We do not mark a price Verified merely because another comparison site published it. Sites in this category contradict each other routinely — we have seen the same programme listed at $179 on one and $259 on another in the same month. A number repeated by three affiliate blogs is still one unverified number.

Frequently asked questions

Is NexLife legitimate?

Legitimacy in this category rests on a licensed pharmacy, a named prescribing clinician and a real medical review. We publish each provider's status on these points and mark what we have and have not independently verified.

How much does NexLife cost?

$147/mo (microdose) to start (verified). See the pricing section for renewal and highest-dose figures.

Does NexLife require a prescription?

Yes. Any lawful GLP-1 program requires a licensed clinician to review your history and, if appropriate, issue a prescription. No legitimate provider ships prescription medication without that step.

Sources

  1. Provider website, terms, pricing and pharmacy-disclosure pages (captured July 12, 2026).
  2. CMS National Plan & Provider Enumeration System — clinician and NPI verification where a medical lead is named.
  3. U.S. Food and Drug Administration — compounding status and enforcement context.
  4. Our published scoring methodology, version 1.0.

Spotted an error? Submit a correction.